Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 29 01 2022
revised: 04 07 2022
accepted: 06 07 2022
pubmed: 16 7 2022
medline: 25 11 2022
entrez: 15 7 2022
Statut: ppublish

Résumé

Serogroup W and Y invasive meningococcal disease increased globally from 2000 onwards. Responding to a rapid increase in serogroup W clonal complex 11 (W:cc11) invasive meningococcal disease, the UK replaced an adolescent booster dose of meningococcal C conjugate vaccine with quadrivalent MenACWY conjugate vaccine in 2015. By 2018, the vaccine coverage in the eligible school cohorts aged 14 to 19 years was 84%. We assessed the impact of the MenACWY vaccination programme on meningococcal carriage. An observational study of culture-defined oropharyngeal meningococcal carriage prevalence before and after the start of the MenACWY vaccination programme in UK school students, aged 15 to 19 years, using two cross-sectional studies: 2014 to 2015 "UKMenCar4" and 2018 "Be on the TEAM" (ISRCTN75858406). A total of 10 625 participants preimplementation and 13 438 postimplementation were included. Carriage of genogroups C, W, and Y (combined) decreased from 2.03 to 0.71% (OR 0.34 [95% CI 0.27-0.44], p < 0.001). Carriage of genogroup B meningococci did not change (1.26% vs 1.23% [95% CI 0.77-1.22], p = 0.80) and genogroup C remained rare (n = 7/10 625 vs 17/13 438, p = 0.135). The proportion of serogroup positive isolates (i.e. those expressing capsule) decreased for genogroup W by 53.8% (95% CI -5.0 - 79.8, p = 0.016) and for genogroup Y by 30.1% (95% CI 8.946·3, p = 0.0025). The UK MenACWY vaccination programme reduced carriage acquisition of genogroup and serogroup Y and W meningococci and sustained low levels of genogroup C carriage. These data support the use of quadrivalent MenACWY conjugate vaccine for indirect (herd) protection.

Identifiants

pubmed: 35840033
pii: S1198-743X(22)00368-8
doi: 10.1016/j.cmi.2022.07.004
pii:
doi:

Substances chimiques

MenACWY 0
Vaccines, Conjugate 0
Meningococcal Vaccines 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1649.e1-1649.e8

Investigateurs

Keith A Jolley (KA)
Karen Ford (K)
Hannah Roberts (H)
Karen Palmer (K)
Debbie Suggitt (D)
Nicola Pemberton (N)
Samantha Ray (S)
Mandy Wootton (M)
Shamez N Ladhani (SN)
Daniel Owens (D)
Katrina Cathie (K)
Simon Royal (S)
Neil Oldfield (N)
Roisin Ure (R)
Jennifer Richards (J)
Rebecca Ramsay (R)
Samantha Thomson Hill (ST)
Kaltun Duale (K)

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Jeremy P Carr (JP)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK; Monash University and Monash Children's Hospital, Melbourne, Australia.

Jenny M MacLennan (JM)

Department of Biology, University of Oxford, Oxford, UK.

Emma Plested (E)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK.

Holly B Bratcher (HB)

Department of Biology, University of Oxford, Oxford, UK.

Odile B Harrison (OB)

Department of Biology, University of Oxford, Oxford, UK.

Parvinder K Aley (PK)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK.

James E Bray (JE)

Department of Biology, University of Oxford, Oxford, UK.

Susana Camara (S)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK.

Charlene M C Rodrigues (CMC)

Department of Biology, University of Oxford, Oxford, UK.

Kimberly Davis (K)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK.

Angela Bartolf (A)

St George's Vaccine Institute, Institute of Infection & Immunity, St George's University of London, UK.

David Baxter (D)

Stockport NHS Foundation Trust, UK.

J Claire Cameron (JC)

Public Health Scotland, Glasgow/Edinburgh, Scotland, UK.

Richard Cunningham (R)

University Hospitals Plymouth NHS Trust, Plymouth, UK.

Saul N Faust (SN)

NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.

Katy Fidler (K)

Brighton and Sussex Medical School, Royal Alexandra Children's Hospital, University Hospital Sussex NHS Foundation Trust, Brighton, UK.

Rohit Gowda (R)

Maidstone and Tunbridge Wells NHS Trust, UK.

Paul T Heath (PT)

St George's Vaccine Institute, Institute of Infection & Immunity, St George's University of London, UK.

Stephen Hughes (S)

Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, UK.

Sujata Khajuria (S)

Northamptonshire Healthcare NHS Foundation Trust, UK.

David Orr (D)

Lancashire Teaching Hospitals NHS Foundation Trust, UK.

Mala Raman (M)

University Hospitals Plymouth NHS Foundation Trust, UK.

Andrew Smith (A)

Glasgow Dental Hospital & School, College of Medical, Veterinary & Life Sciences, University of Glasgow, UK.

David P J Turner (DPJ)

School of Life Sciences, University of Nottingham & Nottingham University Hospitals NHS Trust, UK.

Elizabeth Whittaker (E)

Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK; Section of Paediatric Infectious Diseases, Imperial College London, UK.

Christopher J Williams (CJ)

Communicable Disease Surveillance Centre, Public Health Wales, Cardiff, UK.

Christos S Zipitis (CS)

Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, UK.

Andrew J Pollard (AJ)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK.

Jennifer Oliver (J)

Bristol Vaccine Centre, University of Bristol, UK; School of Population Health Sciences, Bristol Medical School, University of Bristol, UK.

Begonia Morales-Aza (B)

Bristol Vaccine Centre, University of Bristol, UK.

Aiswarya Lekshmi (A)

UK Health Security Agency Meningococcal Reference Unit, Manchester Royal Infirmary Manchester, UK.

Stephen A Clark (SA)

UK Health Security Agency Meningococcal Reference Unit, Manchester Royal Infirmary Manchester, UK.

Ray Borrow (R)

UK Health Security Agency Meningococcal Reference Unit, Manchester Royal Infirmary Manchester, UK.

Hannah Christensen (H)

School of Population Health Sciences, Bristol Medical School, University of Bristol, UK.

Caroline Trotter (C)

Department of Veterinary Medicine, University of Cambridge, UK.

Adam Finn (A)

Bristol Vaccine Centre, University of Bristol, UK; School of Population Health Sciences, Bristol Medical School, University of Bristol, UK.

Martin C Maiden (MC)

Department of Biology, University of Oxford, Oxford, UK. Electronic address: martin.maiden@zoo.ox.ac.uk.

Matthew D Snape (MD)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH